Ultragenyx Pharmaceutical Inc.
NASDAQ:RAREBiotechnology
+$0.81 today
- Market cap
- $1.81B
- Beta
- 0.38
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$6.06
Volume 5.16M
Average 1.81M
RARE Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Ultragenyx Pharmaceutical Inc.NASDAQ: RARE
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue grows, but more slowly than its trailing trend
Q1 FY2026 cost of revenue of $30M rose 4.7% year over year, behind the +25.2% change in trailing-twelve-month cost of revenue. Sequentially, it rose 3.4% from the prior quarter. Over 3 fiscal years it compounded at +56.7% a year.
Context
- Cost of revenue amounted to 16.2% of revenue in FY2025, up 2.5 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +4.7% toward the trailing-twelve-month pace of +25.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 109M USD
- Year-over-year change
- +42.1%
- 4-year CAGR
- +61.5%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 109M | +42.1% |
| FY2024 | 2024-12-31 | 76.73M | +69.7% |
| FY2023 | 2023-12-31 | 45.21M | +59.6% |
| FY2022 | 2022-12-31 | 28.32M | +76.9% |
| FY2021 | 2021-12-31 | 16.01M | — |
Cost of Revenue vs competitors
How RARE compares with its peers on the latest reported figures
- RARE's LTM Mar 2026 cost of revenue of $109.99M is the 3rd highest of the 11 companies compared; the peer median is $27.22M.
- Its year-over-year change of +25.2% is the 6th highest of 11, against a peer median of +67.0%.
- Cost of revenue amounts to 16.4% of revenue for RARE, versus a peer median of 25.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $206.11B | +35566.9% | +13.6% | 20.1% | |
| LTM Jun 2026 | $180.19M | +250.5% | +17.1% | 17.9% | |
| LTM Mar 2026 | $109.99M | +25.2% | +56.7% | 16.4% | |
| LTM Mar 2026 | $99.22M | -12.1% | -54.4% | 112.4% | |
| LTM Mar 2026 | $87.94M | +139.2% | -28.1% | 100.1% | |
| LTM Jun 2026 | $47.45M | +428.8% | +101.9% | 6.7% | |
| LTM Mar 2026 | $6.99M | +800.8% | +50.4% | 48.1% | |
| LTM Mar 2026 | $6.67M | -73.5% | — | 8.4% | |
| LTM Mar 2026 | $4.68M | -49.7% | -20.4% | 25.9% | |
| LTM Mar 2026 | $2.15M | -8.3% | — | — | |
| LTM Mar 2026 | $1.03M | -5.2% | — | 205.7% | |
| Peer median (excluding RARE) | $27.22M | +67.0% | +13.6% | 25.9% | |
Competitors are the stored peer set for RARE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 351.41M | 363.33M | 434.25M | 560.23M | 673M |
| Cost of Revenue | 16.01M | 28.32M | 45.21M | 76.73M | 109M |
| Gross Profit | 335.4M | 335.01M | 389.04M | 483.5M | 564M |
| Gross Margin | 95.4% | 92.2% | 89.6% | 86.3% | 83.8% |
| Research & Development | 497.15M | 705.79M | 648.45M | 697.87M | 750M |
| Selling, General & Admin | 219.98M | 278.14M | 309.8M | 321.61M | 349M |
| Operating Expenses | 717.14M | 983.93M | 958.25M | 1.02B | 1.1B |
| Depreciation & Amortization | 13.24M | 18.22M | 26.01M | 35.54M | 35M |
| EBITDA | (410.32M) | (640.49M) | (516.45M) | (469M) | (474M) |
| EBITDA Margin | -116.8% | -176.3% | -118.9% | -83.7% | -70.4% |
| Operating Income | (381.74M) | (648.92M) | (569.21M) | (535.97M) | (535M) |
| Operating Margin | -108.6% | -178.6% | -131.1% | -95.7% | -79.5% |
| Interest Income | 1.93M | 11.07M | 26.69M | 36.51M | 25M |
| Interest Expense | 29.42M | 43.02M | 66M | 63.04M | 62M |
| Other Income / Expenses | (71.24M) | (52.81M) | (39.26M) | (31.61M) | (36M) |
| Income Before Tax | (452.98M) | (701.73M) | (608.46M) | (567.59M) | (571M) |
| Pre-Tax Margin | -128.9% | -193.1% | -140.1% | -101.3% | -84.8% |
| Income Tax Expense | 1.04M | 5.7M | (1.83M) | 1.6M | 4M |
| Net Income | (454.03M) | (707.42M) | (606.64M) | (569.18M) | (575M) |
| Net Margin | -129.2% | -194.7% | -139.7% | -101.6% | -85.4% |
| EPS (Basic) | (6.70) | (10.12) | (8.25) | (6.29) | (5.83) |
| EPS (Diluted) | (6.70) | (10.12) | (8.25) | (6.29) | (5.83) |
| Weighted Avg Shares | 67.8M | 69.91M | 73.54M | 90.54M | 98.6M |
| Weighted Avg Shares (Diluted) | 67.8M | 69.91M | 73.54M | 90.54M | 98.6M |
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
Intrinsic Alpha fair value
Locked
Current Price
$17.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.